• 구독신청
  • My스크랩
  • 지면신문
FNTIMES 대한민국 최고 금융 경제지
ad

What is the strategy of Celltrion Chairman Seo Jung-jin, who created the '1 trillion blockbuster', to achieve 'KRW 10 trillion in sales within 3 years'?

김나영 기자

steaming@fntimes.com

기사입력 : 2024-12-03 16:18

Celltrion Ramsima, sales this year exceed KRW 1 trillion… first in 130 years of pharmaceutical and biotechnology history
"Sales will reach KRW 5 trillion next year, KRW 10 trillion in 2027… CDMO plant construction begins next year"
Ultimately, a plan to enter the 'CRDMO' business from basic research

Chairman Seo Jung-jin of Celltrion is speaking at an investment briefing in Hong Kong on the 27th of last month. / Photo = YouTube broadcast capture

Chairman Seo Jung-jin of Celltrion is speaking at an investment briefing in Hong Kong on the 27th of last month. / Photo = YouTube broadcast capture

이미지 확대보기
[Korea Financial Times, Kim Nayoung] Celltrion Chairman Seo Jung-jin promised to achieve KRW 5 trillion in sales next year and 10 trillion won within 3 years, and attention is focused on his methodology. With the performance of the new drug Zimfentra (Remsima SC), which grew into a '1 trillion blockbuster' this year, the plan is to transform into a new drug development company that surpasses biosimilars (biopharmaceutical generic drugs), which were the existing growth engine.

According to industry sources on the 3rd, Chairman Seo Jung-jin said at an investor meeting in Hong Kong on the 27th of last month, "We are expected to achieve KRW 3.5 trillion in sales this year. Our goal for next year is KRW 5 trillion."

Chairman Seo's confidence comes from Remsima. Remsima is an infliximab-based immunotherapy drug in a subcutaneous injection (SC) formulation. Chairman Seo began development in 2006 and received approval from the U.S. Food and Drug Administration (FDA) in 10 years. This is the first product in the world to successfully convert infliximab, which previously existed only as an intravenous (IV) injection, into a SC form.

Ramsima has been evaluated as changing the lives of patients with its simple administration method, and has rapidly spread in global markets such as Europe. Ramsima has taken the top spot in market share in just five years since its launch, surpassing the original drug, Johnson & Johnson's 'Remicade'. According to pharmaceutical market research firm IQVIA, the Ramsima product group accounted for 74% market share in the five major European countries (EU5) as of the fourth quarter of last year. It was launched as a new drug in the US in March of this year in recognition of its differentiation, and has recently signed a contract with prescription drug management companies such as ExpressScripts to supply the product.

Ramsima is certain to exceed KRW 1 trillion in sales this year. As of the third quarter of last year, Ramsima's cumulative sales were KRW 979.7 billion. Considering that Ramsima's quarterly sales are approximately KRW 300 billion, annual sales this year are expected to reach KRW 1.2 trillion. It is the first time in the 130-year history of the domestic pharmaceutical and bio industry that a single product has exceeded 1 trillion won in sales.

Chairman Seo is challenging KRW 5 trillion in sales next year based on the cash cow called Ramsima. He said confidently, "We sold more than KRW 1 trillion worth of Ramsima this year. I think it will not be difficult to sell more than KRW 1 trillion in 2025 as well." He continued, "Our goal is to achieve a total of KRW 5 trillion in sales, including KRW 400 billion for Truxima (blood cancer treatment) and KRW 200-300 billion for the remaining products."

Celltrion headquarters. /Photo courtesy of Celltrion

Celltrion headquarters. /Photo courtesy of Celltrion


Chairman Seo is drawing a bigger picture by expanding the business model. He plans to go beyond the biosimilar field and enter the contract research, development and manufacturing (CRDMO) business, including new drugs. This is a model in which Celltrion provides basic research to customers by turning technologies it has secured, such as messenger ribonucleic acid (mRNA) and microbiome, into services.
Chairman Seo said, “Celltrion started with biosimilars, but it is no longer a specialized company for biosimilar products,” and “It has more solid value than any other pharmaceutical company. Please view it as a company that is prepared for the present and the future.”

It seems to be a strategy to get ahead of the curve in the increasingly overheated rather than just staying there. Chairman Seo has been emphasizing the development of new drug for a long time. In the early stages of the business, the company started with the contract manufacturing (CMO) model, but as it accumulated development know-how, it learned the competitiveness of new drugs, such as high pricing and patent protection.

Accordingly, Chairman Seo plans to establish research institutes in the US, India, and Europe and develop various modalities (treatments) such as multiple antibodies, vaccines, and microbiomes. Antibody-drug conjugate (ADC)-based candidate substances are already under development. Chairman Seo also revealed plans to enter Phase 1 clinical trials next year for half of the six ADC candidates currently under development.

As the first step toward CRDMO, we will first focus on contract development and manufacturing (CDMO), which is the current industry trend. This month, we decided to establish a 100% subsidiary CDMO corporation with KRW 1.5 trillion in funds. Starting next year, we plan to start construction on a CDMO plant with a total capacity of 200,000 liters in Korea and achieve sales by 2028.

Chairman Seo said, “We will be able to provide deeper and broader services than existing CRDMO companies. Full-scale sales will occur in 2028,” and emphasized, “We will achieve sales of KRW 5 trillion next year, KRW 7 trillion in 2026, and KRW 10 trillion in 2027, and achieve results without the excuse of being a bio company.”

Kim Nayoung, Korea Finacial Times (steaming@fntimes.com)

데일리 금융경제뉴스 FNTIMES - 저작권법에 의거 상업적 목적의 무단 전재, 복사, 배포 금지
Copyright ⓒ 한국금융신문 & FNTIMES.com

기자의 기사 더보기 전체보기

가장 핫한 경제 소식! 한국금융신문의 ‘추천뉴스’를 받아보세요~

KFT Topic 다른 기사

1 Hanwha Solutions’ Pretax Profit Owes to Asset Sale, Not Core Business Hanwha Solutions’ third-quarter pretax profit turned positive, but the driver was not its core business. It was a single asset sale. The company sold intangible assets with a book value of KRW 12.5 billion and booked a gain of KRW 199.7 billion. Without that gain, this year’s third quarter would show a pretax loss of KRW 176.3 billion.The proceeds from the disposal differ by only KRW 0.8 billion from the amount of fixed assets Hanwha Solutions sold to TransGrid Energy, a Hanwha Group affiliate, over the same period. TransGrid Energy is a subsidiary of a joint venture in which Hanwha Solution 2 Lotte Chemical Pays Down JV Debt With KRW 600 Billion as Its Own Loans Get a Three-Year Reprieve Lotte Chemical contributed KRW 600 billion to help its joint venture H&L Advanced repay existing borrowings. But it has also taken on an impairment loss on its JV shares and faces additional funding support obligations. The value of the shares recognized in the merger-date accounting was less than half the per-share value assessed by an external valuation firm when the merger ratio was set. While pouring large sums into improving the JV’s finances, Lotte Chemical itself has agreed with its creditors to a three-year deferral of repayment on its covenant debt.According to the Financial Supe 3 S-Oil Hits Record Profit, but Shares Sink 40% as Shaheen Bet Looms S-Oil posted record quarterly operating profit in the third quarter of this year, yet its share price has fallen about 40% from its peak.Despite strong results in refining and lubricants, earnings are expected to decline next year. The company also faces the task of proving the profitability of the petrochemical project Shaheen, in which it has invested more than KRW 9 trillion, amid concerns over oversupply.S-Oil reported third-quarter revenue of KRW 11.9687 trillion and operating profit of KRW 1.4067 trillion. Operating profit surged 514% from a year earlier and beat the market consensus by
ad
ad
ad

한국금융 포럼 사이버관

더보기

FT카드뉴스

더보기
[카드뉴스] 성북동 언덕길, 만해의 집을 만나다
[카드뉴스] 약재 향 따라 걷는 서울약령시
[그래픽 뉴스] ‘순대’가 경제용어라고? 순(純)대외자산, 한국의 진짜 해외자산은 얼마일까?
[그래픽 뉴스] ISA 대개편! 나에게 유리한 계좌는?
[그래픽 뉴스] 미국 증시 새로운 키워드 'MANGOS'

FT도서

더보기